| 2 min read
A new alternative approach to antibody-drug conjugates takes advantage of cancer cells’ need for fuel — first by encouraging them to overdose on glucose and then by blocking its backup source of fat.
| 2 min read
A new study showed environmental bacteria can transfer resistance genes to pathogens inside human lungs that were previously sensitive to antibiotics. The findings could prompt new treatments that block the gene transfer.
| 5 min read
Montara Therapeutics is taking a different approach to CNS drug development by using the blood-brain barrier to restrict drug activity outside the brain and reduce dose-limiting toxicities.
| 3 min read
Analysis of two pivotal Yescarta clinical trials revealed that patients' germline DNA influences both toxicity risk and CAR T expansion, opening new opportunities for smarter cell therapy design.
| 4 min read
Positive results for GLP-1 drugs in alcohol use disorder, a new collaboration to advance in vivo CAR T therapies, Phase 3 readouts in oncology, rare disease, and vitiligo, and more led the news this week.News
| 5 min read
Wobble Genomics is using long-read RNA sequencing to reveal the molecular signals that determine whether a cancer treatment will work.
| 4 min read
By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short.
| 3 min read
The science being built right now in discovery labs is what acquirers are already looking for.
| 3 min read
Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease.
| 2 min read
The deal brings a first-in-class anti-CD122 antibody with early clinical validation in vitiligo and celiac disease into argenx's pipeline.
| 4 min read
Positive results in metabolic disease, a possible vaccine to treat the current Ebola outbreak, new cancer drug targets, and more led the news this week.
Cancer Research News
Phase Advance is using mechanistic virtual patient models to predict how LEAF4Life's hypoxia-targeting therapy could perform across multiple indications.
Learn how patient-derived tumor organoids, AI, and phenotypic screening are advancing the discovery of small molecule therapeutics.
Editor's Pick
Born to differentiate and heal, mesenchymal stem cells carry great potential for treating a wide spectrum of diseases.
In a journey fraught with heartache and persistence, medical research giants paved the way for successful bone marrow transplantation.
Multimedia
Learn how developmental and reproductive toxicology study selection supports regulatory decision-making and generates meaningful nonclinical safety data.
Philip Wills, Chief Commercial Officer of the Cell & Gene Therapy Division at Catalent, reflects on how the gene therapy industry is evolving from early scientific breakthroughs to commercial maturity.
